Quantitative multiparametric MRI allows safe surgical planning in patients undergoing liver resection for colorectal liver metastases: report of two patients

Pulkit Sethi, Navamayooran Thavanesan, Fenella Ks Welsh, John Connell, Elisabeth Pickles, Matt Kelly, Jonathan A Fallowfield, Timothy J Kendall, Damian J Mole, Myrddin Rees, Pulkit Sethi, Navamayooran Thavanesan, Fenella Ks Welsh, John Connell, Elisabeth Pickles, Matt Kelly, Jonathan A Fallowfield, Timothy J Kendall, Damian J Mole, Myrddin Rees

Abstract

It is not uncommon for clinicians to encounter varying degrees of hepatic steatosis in patients undergoing resection for colorectal liver metastases (CRLM). Magnetic resonance imaging is currently the preferred investigation for identification and pre-operative planning of these patients. An objective assessment of liver quality and degree of steatosis is paramount for planning a safe resection, which is seldom provided by routine MRI sequences. We studied two patients who underwent an additional pre-operative multiparametric MRI scan (LiverMultiScanTM) as a part of an observational clinical trial (HepaT1ca, NCT03213314) to assess the quality of liver. Outcome was assessed in the form of post-hepatectomy liver failure. Both patients (Patient 1 and 2) had comparable pre-operative characteristics. Both patients were planned for an extended right hepatectomy with an estimated future liver remnant of approximately 30%. Conventional preoperative contrast MRI showed mild liver steatosis in both patients. Patient one developed post-hepatectomy liver failure leading to prolonged hospital stay compared to patient two who had uneventful post-operative course. Retrospective evaluation of multiparametric MRI scan revealed findings consistent with fibro-inflammatory disease and steatosis (cT1 829 ms, PDFF 14%) for patient 1 whereas patient two had normal parameters (cT1 735 ms, PDFF 2.4%). These findings corresponded with the resection specimen histology. Multiparametric MRI can objectively evaluate future liver health and volume which may help refine surgical decision-making and improve patient outcomes.

Conflict of interest statement

Conflicts of interest: JJC, EP and MK are employees and shareholders at Perspectum Ltd. TJK undertakes consultancy work for Perspectum Ltd on an unrelated project. There are no other actual or perceived conflicts of interest to declare.

© 2021 The Authors. Published by the British Institute of Radiology.

Figures

Figure 1.
Figure 1.

References

    1. Swan PJ, Welsh FKS, Chandrakumaran K, Rees M. Long-Term survival following delayed presentation and resection of colorectal liver metastases. Br J Surg 2011; 98: 1309–17. doi: 10.1002/bjs.7527
    1. Khan AS, Garcia-Aroz S, Ansari MA, Atiq SM, Senter-Zapata M, Fowler K, et al. . Assessment and optimization of liver volume before major hepatic resection: current guidelines and a narrative review. Int J Surg 2018; 52: 74–81. doi: 10.1016/j.ijsu.2018.01.042
    1. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey J-N, Abdalla EK. Chemotherapy-Associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274–86. doi: 10.1002/bjs.5719
    1. Robinson SM, Wilson CH, Burt AD, Manas DM, White SA. Chemotherapy-Associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 4287–99. doi: 10.1245/s10434-012-2438-8
    1. Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, et al. . Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol 2018; 91: 20170959. doi: 10.1259/bjr.20170959
    1. Gómez-Ramírez J, Martín-Pérez E, Amat CG, Sanz IG, Bermejo E, Rodríguez A, et al. . Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases. Cir Esp 2010; 88: 404–12. doi: 10.1016/S2173-5077(10)70047-8
    1. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, et al. . Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2011; 18: 421–30. doi: 10.1245/s10434-010-1317-4
    1. Chan G, Hassanain M, Chaudhury P, Vrochides D, Neville A, Cesari M, et al. . Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. HPB 2010; 12: 277–84. doi: 10.1111/j.1477-2574.2010.00170.x
    1. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007–16. doi: 10.1016/S0140-6736(08)60455-9
    1. Hoad CL, Palaniyappan N, Kaye P, Chernova Y, James MW, Costigan C, et al. . A study of T₁ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR Biomed 2015; 28: 706–14. doi: 10.1002/nbm.3299
    1. Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, et al. . Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 2014; 60: 69–77. doi: 10.1016/j.jhep.2013.09.002
    1. McDonald N, Eddowes PJ, Hodson J, Semple SIK, Davies NP, Kelly CJ, et al. . Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. Sci Rep 2018; ; 8: 918915. doi: 10.1038/s41598-018-27560-5
    1. Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, et al. . Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 2016; 64: 308–15. doi: 10.1016/j.jhep.2015.10.009
    1. Mole DJ, Fallowfield JA, Welsh F, Sherif A, Kendall TJ, Semple SK.;in press Quantitative magnetic resonance imaging predicts individual future liver performance after liver resection for cancer. PLoS ONE.
    1. Hutton C, Gyngell ML, Milanesi M, Bagur A, Brady M. Validation of a standardized MRI method for liver fat and T2* quantification. PLoS One 2018; 13: e0204175. doi: 10.1371/journal.pone.0204175
    1. Murakami Y, Abe T, Hashiguchi A, Yamaguchi M, Saito A, Sakamoto M. Color correction for automatic fibrosis quantification in liver biopsy specimens. J Pathol Inform 2013; 4: 36. cited 2020 Nov 26. doi: 10.4103/2153-3539.124009
    1. Mole DJ, Fallowfield JA, Kendall TJ, Welsh F, Semple SI, Bachtiar V, et al. . Study protocol: HepaT1ca - an observational clinical cohort study to quantify liver health in surgical candidates for liver malignancies. BMC Cancer 2018; 18: 890. doi: 10.1186/s12885-018-4737-3
    1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21. doi: 10.1002/hep.20701
    1. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. . Posthepatectomy liver failure: a definition and grading by the International Study group of liver surgery (ISGLS. Surgery 2011; 149: 713–24. doi: 10.1016/j.surg.2010.10.001
    1. Mojtahed A, Kelly CJ, Herlihy AH, Kin S, Wilman HR, McKay A, et al. . Reference range of liver corrected T1 values in a population at low risk for fatty liver disease—a UK Biobank sub-study, with an appendix of interesting cases. Abdom Radiol 2019; 44: 72–84. doi: 10.1007/s00261-018-1701-2

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe